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Abstract 
New peptides derived from the natural antimicrobial temporin B were obtained. The 
design, the antimicrobial activity as well as the characterization of the secondary structure 
of peptides in the presence of bacterial cells is here described. We identified position 6 of 
temporin B as the most suitable for the introduction of acyl chains and we identified 
TB_KKG6K as the most active analogue against Gram positive and Gram negative 
bacteria as compared to natural temporin B and to TB_KKG6A. 
1 Introduction 
Natural antimicrobial peptides are largely investigated due to their broad spectrum of 
action and to their scarce ability to induce resistance in bacterial cells. They are interesting 
scaffolds for the development of new and more potent antibiotics. Conjugation of peptides 
to lipid chains has been demonstrated as a useful strategy to improve and expand the 
activity spectrum of these compounds. Many examples are reported in the literature, 
showing how, generally, conjugation at the N or C terminus of a peptide with a lipid chain 
results in an enhancement of its biological activity. Conjugation at the C-terminus of the 
peptide lactoferricin by a C12 acyl chain enhances its antimicrobial activity as well as its 
affinity for lipid A.[1] Modification of the ultrashort peptide OOWW by lauric acid at the N-
terminus results in an increased antimicrobial effect against planktonic and biofilm forms of 
Gram positive microorganisms.[2] Recent studies carried out on beta defensin analogues 
demonstrated that N-terminal acylation by a C8-C10 chain positively affects the 
antimicrobial activity of compounds: modified peptides show rapid killing kinetics and 
synergism with conventional antibiotics.[3] It has been hypothesized that lipidated peptides 
act by targeting the bacterial plasma membrane, as well as some natural lipidated 
peptides [4][5]. 
With the aim to obtain potent antimicrobial peptides, we designed a series of peptides 
analogues of temporin B. We had previously demonstrated that addition of two extra 
lysines at the N-terminus[6] and substitution of the glycine 6 residue by an alanine in 
temporin B results in a peptide, named TB_KKG6A (sequence: KKLLPIVKNLLKSLL), 
showing activity at low concentrations against Gram positive and Gram negative bacteria, 
while the natural temporin B is only active against Gram positive bacteria.[7] The three-
dimensional structure of the peptide obtained by NMR either in the presence of E.coli LPS 
and in the presence of E.coli cells shows that the peptide assumes an α-helical 
conformation.[7a, 8] NMR paramagnetic relaxation experiments, carried out to detect the 
orientation of the peptide with respect to LPS revealed that side chains of Pro3, Ala 6, Asn 
7, Leu12 and 13 penetrated the LPS. The side chain of Lys10 was found in two different 
orientations: either on the surface and inside the LPS. Saturation transfer difference 
experiments carried out on the peptide TB_KKG6A in the presence of E.coli cells 
confirmed that residues 3, 6 and 10 are in close contact with bacterial cells[8].  
We hypothesized that the replacement of amino acids in positions which seem to be 
involved hydrophobic interactions with the LPS by acylated residues may result in an 
increase of their antimicrobial activity. For these reason we synthesized a number of 
temporin B analogues, and tested the effect of the position and length of the acyl chain on 
the antimicrobial activity of the peptides. Secondary structure of the peptides in the 
presence of Gram positive and Gram negative bacterial cells was also investigated.  
 
2 Results  
2.1 Design and antimicrobial activity . 
Based on the results of NMR experiments of the peptide TB_KKG6A in the presence of 
E.coli LPS and cells, we designed an initial set of molecules (peptides 1 to 6), in which 
Pro3, Gly6 and Asn7, found to penetrate LPS micelles, were replaced by acylated lysine 
residues (Table 1).  
Table 1. Peptide sequences, names and numbers 
Peptide number Peptide sequence1 Name1 
1 KKLLK(Pal)IVANLLKSLL TB_KKP3K(Pal)G6A 
2 KKLL K(Oct)IVANLLKSLL TB_KKP3K(Oct)G6A 
3 KKLLPIV K(Pal)NLLKSLL TB_KKG6K(Pal) 
4 KKLLPIV K(Oct)NLLKSLL TB_KKG6K(Oct) 
5 KKLLPIVA K(Pal)LLKSLL TB_KKG6AN7K(Pal) 
6 KKLLPIVA K(Oct)LLKSLL TB_KKG6AN7K(Oct) 
7 KKLLPIVKNLLKSLL TB_KKG6K 
8 KKLLPIVK(Ac)NLLKSLL TB_KKG6K(Ac) 
9 KKLLPIVK(DAVA)NLLKSLL TB_KKG6K(DAVA) 
10 KKLLPIVK(Ahx)NLLKSLL TB_KKG6K(Ahx) 
11 KKLLPIVK(BrHx)NLLKSLL TB_KKG6K(BrHx) 
12 KKLLPIVK(Aund)NLLKSLL TB_KKG6K(Aund) 
1BrHx: 6-bromo hexanoic acid; Aund: 11-amino undecanoic acid 
These experiments were aimed at identifying the position in which the acylation produced 
beneficial effects on the antimicrobial activity. Residues in position 10, 12 and 13, that are 
also included between those involved in the penetration of LPS, were not modified as 
these were demonstrated to be crucial to maintain the activity of the temporin B peptide.[7a] 
To start, we investigated killing kinetics for peptides 1 to 6, bearing in positions 3 or 6 or 7 
lysines with chains of two different length, octanoic acid and palmitic acid respectively on 
two different bacteria, E.coli and S.epidermidis (Figure 1).  
 
Figure 1. Antimicrobial activity of palmitoylated and octanoylated peptides. Effect of 24 
hours treatment of bacterial cells with indicated peptides at two different concentrations. 
Relative growth of bacteria was calculated as the ratio of the OD600 after 24 hours 
incubation of peptides with cells and at time zero. C1: control cells, C2: gentamicin, used 
at 1.5 µg/mL for E.coli cells and at 1 µg/ml for S.epidermidis cells 
 
Replacement of amino acids in position 3 and 7 by acylated lysines yielded peptides with a 
very low antimicrobial activity against E.coli. Replacement of proline 3 by octanoylated 
lysine yielded peptide n.2; antimicrobial activity against S.epidermidis required a 
concentration of 50 μM. Replacement of glycine 6 by acylated lysines resulted in promising 
analogues (Figure 1 and 2): the octanoylated peptide (peptide n.4) showed very strong 
activity either against E.coli and S.epidermidis at the lowest concentration tested and fast 
killing. The palmitoylated peptide (peptide number 3) was active against E.coli only at high 
concentration, while the activity against S.epidermidis was modest at both concentrations 
tested. Based on these results we decided to investigate the effect of introduction of acyl 
chains of different length in position 6. We synthesized new analogues, with lysine in 
position 6 (TB_KKG6K) and with lysine acetylated (TB_KKG6K(Ac)), acylated with 5-
amino valeric acid (TB_KKG6K(DAVA)), 6-amino hexanoic acid (TB_KKG6K(Ahx)), 6-
bromo hexanoic acid (TB_KKG6K(BrHx)) and 11-amino undecanoic acid 
(TB_KKG6K(Aund)) (Table 1). MIC for these new set of peptides were determined against 
E.coli, S.epidermidis and P.aeruginosa. Peptides with short acyl chains resulted more 
active than peptides with longer acyl chains, with TB_KKG6K being the most active 
peptide. All peptides show an increased antimicrobial activity as compared to the parent 
TB_KKG6A against P.aeruginosa, with the exception of TB_KKG6K(DAVA) (Table 2).  
 
Table 2. Antimicrobial activity of selected peptides 
 
Peptide 
number 
MIC (µM) 
E. coli S. epidermidis P. aeruginosa 
7 0.2 0.025 2.5 
8 0.5 0.1 2.5 
9 1.25 0.1 15 
10 1.65 0.25 7 
11 1 2.5 5 
12 5 2.5 3 
 
 
 
Figure 2: Killing kinetics of peptides modified in position 6. Relative growth of bacteria was 
calculated as the ratio of the OD600 after the indicated time of incubation of peptides with 
cells and at time zero. 
 
2.2 CD studies 
The secondary structure of the most active peptide TB_KKG6K was investigated in 
phosphate buffer and in the presence of S.epidermidis and E.coli bacterial cells (Figure 3). 
TB_KKG6K is a random coil in phosphate buffer and in the presence of S.epidermidis 
cells. In the presence of E.coli cells, with increasing the incubation time, the negative 
maximum appearing at 200 nm in buffer shifts to 205 nm and a weak band around 222 nm 
appears. We also investigated the secondary structure of TB_KKG6K(Pal) and 
TB_KKG6K(Oct) in the same experimental conditions, with the aim to understand the 
effect of lipidation on the structure of the peptides (Figure 3). The peptide TB_KKG6K(Pal) 
is an α-helix in phosphate buffer; upon interaction with E.coli and S.epidermidis cells 
signals become less intense and noisy. TB_KKG6K(Oct) assumes an α-helical structure in 
phosphate buffer;[9] when the peptide is incubated with E.coli and S.epidermidis cells, CD 
spectra recorded at different time of incubation show one negative maximum around 200 
nm.  
 
 
Figure 3: CD spectra of peptides in phosphate buffer, pH 7 (green), in the presence of 
E.coli cells (grey) or S.epidermidis cells (magenta). 
 
2.3 Critical aggregation concentration 
The critical aggregation concentration was determined for the peptide TB_KKG6K(Pal) 
and TB_KKG6K by fluorescence experiments, using as a probe 8-amino naphtalen 
sulfonic acid. This probe emits between 460 and 480 nm if it is in a hydrophobic 
environment. Emission at 470 nm was plotted against peptide concentration (Figure 4). 
The critical aggregation concentration was evaluated to be 0.26 µM for TB_KKG6K(Pal). 
TB_KKG6K does not aggregate up to 10mM concentration. 
 
Figure 4: Critical aggregation concentration plot for the peptide TB_KKG6K(Pal). 
 
3 Discussion 
The antimicrobial activity of peptides is related to their ability to bind to and disrupt 
bacterial membranes. Electrostatic interactions between the positively charged residues of 
antimicrobial peptides and negatively charged lipopolysaccharide, in case of Gram 
negative bacteria, or teichoic acids, in case of Gram positive bacteria, are responsible for 
the initial interaction of peptides with bacterial cells. Hydrophobic residues instead seem to 
penetrate bacterial membrane, to interact with lipids. Some peptides assume an 
amphipathic structure, that grants a clear separation between the hydrophobic and 
hydrophilic patches,[10] maximizing the interactions between peptides and bacterial 
membranes. TB_KKG6A is not an amphipathic peptide; nevertheless it is highly active 
against Gram positive and Gram negative bacteria. It assumes an α-helical structure in the 
presence of E.coli cells, while it does not show a preferred secondary structure in the 
presence of S.epidermidis cells.[11] Binding of the peptide to E.coli cells causes 
aggregation and death of bacterial cells[12]. With the aim to increase the antimicrobial 
activity of this peptide by reinforcing the hydrophobic interactions of the peptide with 
bacterial cell membrane, we investigated the effect of introduction of acyl chains of 
different length in different positions of the peptides, chosen between those hypothesized 
to penetrate the membrane and not essential for the activity of the peptides, i.e. positions 
3, 6 and 7. The initial screening, carried out replacing Pro3, Ala 6 and Asn 7 of TB_KKG6A 
with either Lys(Pal) and Lys(Oct), revealed that modifications in position 6 are beneficial 
for the activity of the peptide. These results are in accordance with those reported on TB 
analogues obtained by Ala scan experiments, showing that TB_P3A, and TB_N7A were 
less active than TB_G6A.[7a] Peptides modified by the long palmitic acid chain in position 6 
are less active as compared to peptides modified with shorter acyl chains.  
Based on the results of the initial screening we synthesized a new set of analogues 
modified in position 6 by a lysine or an acylated lysine. The most active peptide is 
TB_KKG6K; introduction of a lysine residue with its short acyl side chain and its positive 
charge increases the antimicrobial activity against Gram positive and Gram negative 
bacteria likely because interactions with negatively charged outer membranes are favored. 
The 4 carbon atom chain is likely able to destabilize bacterial membrane, and too short to 
promote aggregation of the peptide. Acetylation of the lysine residue in position 6 reduces 
the activity of the peptide against E.coli and S.epidermidis; the effect of acetylation is 
double: suppression of the positive charge and tiny increase of the acyl chain length. 
When the positive charge is kept fixed at 4 and the acyl chain length is increased, as in 
TB_KKG6K(DAVA), TB_KKG6K(Ahx), TB_KKG6K(Aund) we observe a decrease of the 
antimicrobial activity of the peptides against E.coli and S.epidermidis, suggesting that the 
increase of the hydrophobicity of the peptide is detrimental to the antimicrobial activity. 
Effects of the hydrophobicity on the antimicrobial activity are remarkable for the Gram 
positive bacterium S.epidermidis; the comparison of the activity of the analogs 
TB_KKG6K(Ahx) and TB_KKG6K(BrHx) is consistent with this observation. The activity of 
the peptides was also tested against P.aeruginosa, a Gram negative bacterium. Results in 
this case are difficult to interpret as there is no apparent relationship between the 
hydrophobicity of the peptides and their activity. Importantly, with the exception of 
TB_KKG6K(DAVA), all peptides are more active than TB_KKG6A against P.aeruginosa. 
The presence of acyl chains affects the structure of the peptides. CD reveals that 
TB_KKG6K(Pal) possess an α-helical structure in phosphate buffer, that disappears in the 
presence of bacterial cells. The palmitoylated peptide show a strong tendence to 
aggregate; in fact, the critical aggregation concentration calculated for the peptide 
TB_KKG6K(Pal) is very low, 0.26µM. As reported in the literature, loss of conformational 
freedom due to tethering and confinement leads to folding into defined secondary structure 
motifs.[13] This effect has been reported for other palmitoylated peptide and is likely what 
we are observing here for the palmitoylated peptide.[14] Interactions of TB_KKG6K(Pal) 
aggregates with bacterial cells, either E.coli and S.epidermidis, likely cause disgregation of 
the aggregates that results in a decrease in the intensity of CD spectra in the presence of 
E.coli cells, and also in a change in shape of the spectra in the case of S. epidermidis 
cells. Indeed the free TB_KKG6K(Pal) peptide does not induce massive bacterial cell 
death. Similar results have been obtained also for the peptide TB_KKG6K(Oct). 
TB_KKG6K is unfolded either in buffer and in the presence of S.epidermidis bacterial cells, 
while some degree of secondary structure appears in the presence of E.coli cells. The 
ability to fold upon interaction with E.coli is associated in many cases with the antimicrobial 
activity of the peptide, and this is consistent with results reported for other natural 
peptides, such as temporin L, cecropin A and magainin 2 or obtained upon modification of 
temporin peptides such as TB_KKG6A and LG21.[8, 11, 15]  
4 Conclusions 
We obtained a new set of analogues of the peptide temporin B, showing activity either 
against Gram positive and against Gram negative bacteria. Introduction of short the acyl 
chains in position 6 as well as of lysines at the N-terminus of temporin B positively affects 
the antimicrobial activity of the peptides against E.coli and S.epidermidis. Replacement of 
glycine 6 by a lysine results in the most active peptide. The length of the chain in position 6 
seems to be crucial to determine the antimicrobial activity against S.epidermidis. 
 
5 Experimental procedures 
 
5.1 Peptide synthesis 
Peptides were obtained by solid phase synthesis using standard protocols.[7b, 16] Fmoc-
Lys(Pal)-OH and Fmoc-Lys(Oct)-OH were used for the synthesis of palmitoylated and 
octanoylated peptides; Fmoc 5-amino valeric acid, Fmoc 6-amino hexanoic acid, 6 bromo 
hexanoic acid, Fmoc 11-aminoundecanoic acid were employed for the synthesis of the 
following peptides: TB_KKG6K(DAVA), TB_KKG6K(Ahx), TB_KKG6K(BrHx), 
TB_KKG6K(Aund). Peptide TB_KKG6K(Ac), was obtained starting from the peptide 
anchored to the resin bearing in position 6 a lysine protected with Mtt on the side chain 
and protected at the N-terminus with the Fmoc group. The Mtt was removed by 
consecutive treatments of the resin with a solution of TFA (0.1%)/TIS (5 %) in DCM; upon 
neutralization the peptide was acetylated following standard protocol for peptide solid 
phase acetylation.[17]  
Peptides were purified by RP-HPLC using a gradient of acetonitrile (0.1% TFA) in water 
(0.1% TFA) from 30 to 80% in 20 minutes (the gradient starts after 3 minutes of 
equilibration in 30% acetonitrile) on a Phenomenex Jupiter 10μ Proteo 90 Å (250×10 mm) 
column. LC-MS analysis was performed on a by LC-MS on a LC-MS Agilent Technologies 
6230 ESI-TOF using a Phenomenex Jupiter 3µm C18 (150x2.0 mm) column with a flow 
rate of 0.2 mL/min. Peptides were obtained with a purity >95%, yields were calculated 
based on the amount of pure peptide obtained after purification. 
 
n.1: TB_KKP3K(Pal)G6A. Sequence: KKLLK(Pal)IVANLLKSLL 
Calculated mass (Da): 1931.87 found: 1931.01 [M+2H]2+= 966.50; [M+3H]3+= 644.67; r.t.: 
21.1 min, yield: 30%. 
n.2: TB_KKP3K(Oct)G6A. Sequence: KKLLK(Oct)IVANLLKSLL 
Calculated mass (Da): 1819.64; found: 1820.15 [M+2H]2+= 911.29; [M+3H]3+= 607.83; r.t.: 
14.7 min; yield: 25%. 
n.3: TB_KKG6K(Pal) Sequence: KKLLPIVK(Pal)NLLKSLL 
Calculated mass (Da): 1958.85 g/mol [M+2H]2+= 980.42; [M+3H]3+= 653.95; found: 
1958.23 [M+2H]2+= 980.11; [M+3H]3+= 653.74; r.t.: 22.3 min; yield: 32% 
n.4: TB_KKG6K(Oct) Sequence: KKLLPIVK(Oct)NLLKSLL 
Calculated mass (Da): 1846.62 found: 1847.01 [M+2H]2+= 924.50; [M+3H]3+= 616.67; r.t.: 
16.7, yield 40% 
n.5: TB_KKG6AN7K(Pal)  Sequence: KKLLPIVAK(Pal)LLKSLL  
Calculated mass (Da): 1915.90 found: 1915.45 [M+2H]2+= 958.72; [M+3H]3+= 639.48; r.t.: 
22.7 min; yield:20% 
n.6: TB_KKG6AN7K(Oct) Sequence: KKLLPIVAK(Oct)LLKSLL 
Calculated mass (Da): 1803,62 found: 1803,34 [M+2H]2+= 902.67; [M+3H]3+= 602.11; r.t.: 
17.4 min; yield: 20% 
n.7:TB_KKG6K Sequence: KKLLPIVKNLLKSLL  
Calculated mass (Da): 1719.30; found: 1719.22 [M+2H]2+= 860.62; [M+3H]3+= 574.08; r.t.: 
11.8 min; yield:50% 
n.8: TB_KKG6K(Ac) Sequence: KKLLPIVK(Ac)NLLKSLL 
Calculated mass (Da) 1761.30; found: 1761.26 [M+2H]2+= 881.62; [M+3H]3+= 588.08; 
r.t.:12.1 min; yield: 50% 
n.9: TB_KKG6K(DAVA) Sequence: KKLLPIVK(DAVA)NLLKSLL 
Calculated mass (Da) 1818,45; found: 1818,27 ;[M+2H]2+= 910.14; [M+3H]3+= 607.09; r.t.: 
6.10 min; yield: 40% 
n.10: TB_KKG6K(Ahx) Sequence: KKLLPIVK(Ahx)NLLKSLL 
Calculated mass (Da):1832.15 ; found: 1832.44 [M+2H]2+= 917.22; [M+3H]3+= 612.16; r.t.: 
10.9 min; yield: 45%. 
n.11: TB_KKG6K(BrHx) Sequence: KKLLPIVK(BrHx)NLLKSLL 
Calculated mass (Da):1897,89; found: 1898,34 [M+2H]2+= 950.17; [M+3H]3+= 633.79; r.t.: 
6.40 min; yield: 40% 
n.12: TB_KKG6K(Aund) Sequence: KKLLPIVK(Aund)NLLKSLL 
Calculated mass (Da): 1901.54; found: 1902.37  [M+2H]2+= 952.19; [M+3H]3+= 635.13. r.t.: 
9.2 min; yield: 30%. 
 
5.2 Critical aggregation concentration 
The critical aggregation concentration was determined for the peptide TB_KKG6K(Pal) 
and TB_KKG6K by fluorescence on a Jasco Cary eclipse instrument, setting up the 
excitation wavelength at 350 nm. Increasing concentrations of peptide were titrated into a 
20 µM 8-amino naphtalen sulfonic acid solution in water. Emission at 470 nm was plotted 
against peptide concentration. The critical aggregation concentration was determined at 
the crossing point of the two lines at different slope obtained fitting by a linear regression 
fluorescence intensity before and after aggregation versus the concentration of the 
peptide.  
5.3 Killing kinetics determination 
Killing kinetics were investigated for the peptides on two different bacteria strains: E.coli 
and S.epidermidis. Bacteria were grown on Tryptic Soy Agar Petri dishes at 37°C over 
night before the treatment. The day of treatment a bacterial smear was added to 2 ml of 
LB (Luria-Bertani liquid medium) to obtain 0.5 McFarland units turbidity, corresponding to  
about 1x108 CFU/ml bacterial concentration.[18] A 1.3 μl volume of this bacterial suspension 
were inoculated in 2 mL of LB medium for each test sample to obtain a final bacterial 
concentration of 6.6x104 CFU/ml. Gentamicin was used as positive control at the 
concentration of 1.5 μg/ml for E.coli and 1 μg/ml for S.epidermidis. The treatment was 
carried out at two different concentrations (50 µM and 10 µM) of each peptide. The test 
tubes were incubated at 37°C in shake for 24 hours. The turbidity was measured every two 
hours as proposed by Sutton (2011), using Densitometer DEN-1B (Grant bio). [19] 
 
5.4 Minimum Inhibitory Concentration (MIC) determination 
The MIC assays for the peptides were carried out in triplicate on three bacteria strains 
(E.coli, S.epidermidis and P.aeruginosa) by using the microdilution method. Bacteria were 
grown on Tryptic Soy Agar Petri dishes at 37°C over night. The day of treatment a 
bacterial smear was added to 2 ml of LB or TSB (Tryptic Soy Broth) for E.coli and 
S.epidermidis or P.aeruginosa respectively, to obtain 0.5 McFarland units turbidity (about 
1x108 CFU/ml). [18] Different concentrations of each peptide were added to 2 ml of 
corresponding strain medium inoculated with 1.3 μl of bacterial suspension to obtain a final 
concentration of 6.6x104 CFU/ml, followed by incubation for up to 8 hours at 37°C in 
shake. Gentamicin was used as positive control. Bacterial growth was detected by turbidity 
measurement using Densitometer DEN-1B (Grant bio). MIC was defined as the lowest 
peptide concentration that inhibited bacterial growth. [19]  
 
5.5 Cell cultures for CD experiments 
 
E.coli BL21 (DE3) and S.epidermidis  (ATCC 12228) cells for CD experiments were grown 
in LB medium at 37°C, harvested while in exponential phase (OD600 nm: 0.6–0.8) and 
centrifuged (5000 rpm, 10 min, 4°C). S.epidermidis cells were suspended in Na2HPO4 10 
mM, KH2PO4 2 mM, NaCl 20mM, KCl 2.7 mM, pH 7, centrifuged three times and then 
resuspended in the same buffer at 0.1 OD600. E.coli cells were suspended in 10 mM 
phosphate buffer pH 7, centrifuged three times and then re-suspended in the same buffer 
at 0.1 OD600. [11, 15b]  
 
5.6 CD studies 
Spectra were recorded on a Jasco J715 spectrometer at 25°C using a 0.1 cm quartz cell in 
the range 260-195 nm setting the scanning speed at 200 nm/min, bandwidth 1 nm, 
response time 2s, data pitch 1nm. Peptides concentration for CD measurement was 60 
µM; measurements were performed in : 1) 10 mM sodium phosphate buffer pH 7.0 2) 
Na2HPO4 10 mM, KH2PO4 2 mM, NaCl 20 mM, KCl 2.7 mM at pH 7; 3) E.coli cells 0.1 
OD600 in 10 mM sodium phosphate buffer pH 7.0 4) S.epidermidis cells 0.1 OD600 
Na2HPO4 10 mM, KH2PO4 2 mM, NaCl 20 mM, KCl 2.7 mM at pH 7. Peptide concentration 
was determined measuring the absorbance at 205 nm a Thermo Fisher Scientific Inc 
(Wilmington, Delaware USA) Nanodrop 2000c spectrophotometer. 
Peptides were mixed to the bacterial cells; spectra were recorded every 20 minutes for 2 
hours. 
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